Posted by Michael Wonder on 17 Oct 2017
Cognition Therapeutics receives fast track designation from U.S. FDA for first-in-class Alzheimer's candidate, CT1812
16 October 2017 - Cognition Therapeutics today announced that the U.S. FDA has granted fast track designation to its investigational drug CT1812 for the treatment of patients with Alzheimer’s disease.
CT1812 is a first-in-class, orally administered small molecule that has recently completed a Phase 1b/2 clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease. CT1812 inhibits the binding of beta amyloid (Aß) oligomers to neuronal receptors and facilitates clearance of Aß oligomers into the cerebrospinal fluid. By so doing, CT1812 may decrease the toxic effects of Aß oligomers allowing synapses to regenerate and cognitive performance to return.
